| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.1 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.1 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.05 | 0.1 |